BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug

Reuters11-04

** Shares of drug developer Compass Pathways CMPS.O rise 12.4% to $6.69 premarket

** Co says it is moving up its commercial launch plans for its experimental depression treatment COMP360, by up to a year, following a positive meeting with the U.S. FDA

** CMPS's COMP360 is being developed for people with treatment-resistant depression

** Co now expects to release key data from its ongoing clinical trials in early 2026, as well as additional results from late-stage trials

** COMP360 showed meaningful symptom reduction in earlier trial with no safety issues, co says

** Up to last close, stock up ~57% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580673902?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580673902","market":"nz","top_or_hot":-1,"title":"BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug</title></head><body><p>** Shares of drug developer Compass Pathways <span>CMPS.O</span> rise 12.4% to $6.69 premarket</p><p>** Co says it is moving up its commercial <span>launch plans</span> for its experimental depression treatment COMP360, <span>by up to a year, </span>following a positive meeting with the U.S. FDA</p><p>** CMPS's COMP360 is being developed for people with treatment-resistant depression</p><p>** Co now expects to release key data from its ongoing clinical trials in early 2026, <span>as well as additional results from late-stage trials </span></p><p>** COMP360 showed meaningful symptom reduction in earlier trial with no safety issues, co says</p><p>** Up to last close, stock up ~57% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 20:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug</title></head><body><p>** Shares of drug developer Compass Pathways <span>CMPS.O</span> rise 12.4% to $6.69 premarket</p><p>** Co says it is moving up its commercial <span>launch plans</span> for its experimental depression treatment COMP360, <span>by up to a year, </span>following a positive meeting with the U.S. FDA</p><p>** CMPS's COMP360 is being developed for people with treatment-resistant depression</p><p>** Co now expects to release key data from its ongoing clinical trials in early 2026, <span>as well as additional results from late-stage trials </span></p><p>** COMP360 showed meaningful symptom reduction in earlier trial with no safety issues, co says</p><p>** Up to last close, stock up ~57% YTD</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL4N3WG1A0:1","article_id":"2580673902","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580673902","pubTimestamp":1762260481,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug** Shares of drug developer Compass Pathways CMPS.O rise 12.4% to $6.69 premarket** Co says it is moving up its commercial launch plans for its experimental depression treatment COMP360, by up to a year, following a positive meeting with the U.S. FDA** CMPS's COMP360 is being developed for people with treatment-resistant depression** Co now expects to release key data from its ongoing clinical trials in early 2026, as well as additional results from late-stage trials ** COMP360 showed meaningful symptom reduction in earlier trial with no safety issues, co says** Up to last close, stock up ~57% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4139":"生物科技"},"translate_title":"BUZZ-Compass Pathways加快了抑郁症药物的上市计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"BUZZ-Compass Pathways jumps as it speeds up launch plans for depression drug** Shares of drug developer Compass Pathways CMPS.O rise 12.4% to $6.69 premarket** Co says it is moving up its commercial launch plans for its experimental depression treatment COMP360, by up to a year, following a positive meeting with the U.S. FDA** CMPS's COMP360 is being developed for people with treatment-resistant depression** Co now expects to release key data from its ongoing clinical trials in early 2026, as well as additional results from late-stage trials ** COMP360 showed meaningful symptom reduction in earlier trial with no safety issues, co says** Up to last close, stock up ~57% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580673902","isCrawlerRequest":true}